The US FDA has approved, on Monday Pembrolizumab in combination with carboplatin and paclitaxel, followed by pembrolizumab as a single agent, to treat adult patients with primary, advanced or recurrent endometrial carcinoma.
The approval came after considering data from the phase 3 NRG-GY018 trial (NCT03914612). During tests, it was found that the Pembrolizumab combination reduced disease progression or death compared with Pembrolizumab administered alone.
Endometrial cancer is believed to be the most common gynaecologic cancer in the US. The anti-programmed death receptor-1 (PD-1) therapy works by increasing the immune system's ability to detect and fight tumour cells.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid